Hayley Francies | Senior Staff Scientist

Francies, Hayley

Within the Translational Cancer Genomics group, Hayley's work is focused upon the derivation, charcterisation and use of cancer organoid models for phenotypic screens to identify novel cancer therapies/targets and genetic biomarkers of drug response. Hayley is also the project lead for the Sanger Institute's cell models generation efforts as part of the Human Cancer Models Initiative.

Much of the work within the Translational Cancer Genomics group has been focused upon the use of our extensive cancer cell line collection to conduct high-throughput drug and CRISPR knock-out screens to identify novel therapies and biomarkers of response. However, for many cancer types, the cell line collection fails to encompass the genetic breadth of the disease and thus we are utilising the organoid technology to expand our cell line collection.

Our initial work contributed to evidence in field demonstrating that cancer organoid models faithfully captured the genomics of the tumour of origin as well as much of the genetic breadth of the disease and further were amenable to drug screening. Subsequently, the Sanger Institute is one of the founding members of the Human Cancer Models Initiative, an international effort to derive and characteise the next-generation of cancer models and importantly to make the models and datasets widely available to the research community. 

Publications

  • Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models.

    van der Meer D, Barthorpe S, Yang W, Lightfoot H, Hall C et al.

    Nucleic acids research 2019;47;D1;D923-D929

  • Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.

    Li X, Francies HE, Secrier M, Perner J, Miremadi A et al.

    Nature communications 2018;9;1;2983

  • Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.

    Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarró LM et al.

    Nature medicine 2017;23;12;1424-1435

  • Drug Sensitivity Assays of Human Cancer Organoid Cultures.

    Francies HE, Barthorpe A, McLaren-Douglas A, Barendt WJ and Garnett MJ

    Methods in molecular biology (Clifton, N.J.) 2019;1576;339-351

  • What role could organoids play in the personalization of cancer treatment?

    Francies HE and Garnett MJ

    Pharmacogenomics 2015;16;14;1523-6

  • Prospective derivation of a living organoid biobank of colorectal cancer patients.

    van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F et al.

    Cell 2015;161;4;933-45

  • Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.

    Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE et al.

    Breast cancer research : BCR 2011;13;2;R29

  • Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.

    Gee JM, Nicholson RI, Barrow D, Dutkowski CM, Goddard L et al.

    Hormone molecular biology and clinical investigation 2011;5;2;67-77

  • Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models.

    van der Meer D, Barthorpe S, Yang W, Lightfoot H, Hall C et al.

    Nucleic acids research 2019;47;D1;D923-D929

  • Drug Sensitivity Assays of Human Cancer Organoid Cultures.

    Francies HE, Barthorpe A, McLaren-Douglas A, Barendt WJ and Garnett MJ

    Methods in molecular biology (Clifton, N.J.) 2019;1576;339-351

  • Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.

    Li X, Francies HE, Secrier M, Perner J, Miremadi A et al.

    Nature communications 2018;9;1;2983

  • Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.

    Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarró LM et al.

    Nature medicine 2017;23;12;1424-1435

  • Prospective derivation of a living organoid biobank of colorectal cancer patients.

    van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F et al.

    Cell 2015;161;4;933-45

  • What role could organoids play in the personalization of cancer treatment?

    Francies HE and Garnett MJ

    Pharmacogenomics 2015;16;14;1523-6

  • Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.

    Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE et al.

    Breast cancer research : BCR 2011;13;2;R29

  • Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.

    Gee JM, Nicholson RI, Barrow D, Dutkowski CM, Goddard L et al.

    Hormone molecular biology and clinical investigation 2011;5;2;67-77

Francies, Hayley
Hayley's Timeline
2016

Identified as 1 of 50 Movers and Shakers in the 2016 Biobeat BioBusiness list

NC3R's Highly Commended Award

Senior Staff Scientist at Wellcome Sanger Institute

2013

Postdoctoral Fellow at the Wellcome Sanger Institute

Graduated from Cardiff University following the completion of PhD: 'Characterising Response and Resistance Mechanisms to Faslodex in Breast Cancer'

2009

Graduated from University of Portsmouth, BSc Pharmacology